
    
      The purpose of our current randomized clinical trial is to compare phacoemulsification with
      endoscopic cyclophotocoagulation (PHE) versus phacoemulsification alone (PHA) in patients
      with either primary angle closure (PAC) or primary angle closure glaucoma (PACG) presenting
      with cataract or a clear lens.
    
  